AR015252A1 - Moleculas de polinucleotido aisladas, moleculas de oligonucleotido, vector recombinante, celula hospedadora transformada, polipeptido aislado osustancialmente purificado, anticuerpo aislado, construccion genetica, celula de neospora modificada, procedimiento para prepararla, vacuna contra laneosporo - Google Patents
Moleculas de polinucleotido aisladas, moleculas de oligonucleotido, vector recombinante, celula hospedadora transformada, polipeptido aislado osustancialmente purificado, anticuerpo aislado, construccion genetica, celula de neospora modificada, procedimiento para prepararla, vacuna contra laneosporoInfo
- Publication number
- AR015252A1 AR015252A1 ARP990101308A ARP990101308A AR015252A1 AR 015252 A1 AR015252 A1 AR 015252A1 AR P990101308 A ARP990101308 A AR P990101308A AR P990101308 A ARP990101308 A AR P990101308A AR 015252 A1 AR015252 A1 AR 015252A1
- Authority
- AR
- Argentina
- Prior art keywords
- molecules
- cell
- antibody
- isolated
- transformed
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- 230000002068 genetic effect Effects 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 238000010276 construction Methods 0.000 title 1
- 241001147662 Neospora caninum Species 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 101150010973 GRA1 gene Proteins 0.000 abstract 2
- 102100024017 Glycerol-3-phosphate acyltransferase 3 Human genes 0.000 abstract 2
- 101000904259 Homo sapiens Glycerol-3-phosphate acyltransferase 3 Proteins 0.000 abstract 2
- 241001147660 Neospora Species 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 101100056797 Canis lupus familiaris SAG gene Proteins 0.000 abstract 1
- 101150073248 GRA2 gene Proteins 0.000 abstract 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 abstract 1
- 101000692878 Homo sapiens Regulator of MON1-CCZ1 complex Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 102100026436 Regulator of MON1-CCZ1 complex Human genes 0.000 abstract 1
- 101100532512 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SAG1 gene Proteins 0.000 abstract 1
- 230000002457 bidirectional effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente proporciona moléculas de polinucleotido aisladas que comprenden secuencias de nucleotidos que codifican las proteínas GRA1, GRA2, SAG1, MIC1 yMAG1 de Neospora caninum, así como vectores recombinantes, células hospedadoras transformadas yproteínas expresadas de forma recombinante. La presente ademásproporciona una molécula de polinucleotido que comprende la secuencia de nucleotidos del promotor bidireccional GRA1/MAG1 de N. caninum. La presente ademásproporciona construcciones genéticas basadas en las moléculas de polinucleotido de la presente invencion que son utiles en la preparacion de cepas modificadasde células de Neospora para uso en vacunas contra la neosporosis. También se proporcionan polipéptidos aislados o sustancialmente purificados, métodos parapreparar células de Neospora modificadas, moleculas de oligonucleotido, vacuna contra neosporosis; método para prepararla, método para vacunar un mamífero yequipo de vacunacion. También se describen anticuerpos aisladosque reaccionan contra N. caninum.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7938998P | 1998-03-26 | 1998-03-26 | |
| US11228298P | 1998-12-15 | 1998-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015252A1 true AR015252A1 (es) | 2001-04-18 |
Family
ID=26761953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101308A AR015252A1 (es) | 1998-03-26 | 1999-03-24 | Moleculas de polinucleotido aisladas, moleculas de oligonucleotido, vector recombinante, celula hospedadora transformada, polipeptido aislado osustancialmente purificado, anticuerpo aislado, construccion genetica, celula de neospora modificada, procedimiento para prepararla, vacuna contra laneosporo |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6600027B1 (es) |
| EP (1) | EP0953641A3 (es) |
| JP (5) | JPH11332583A (es) |
| CN (1) | CN1232087A (es) |
| AR (1) | AR015252A1 (es) |
| AU (1) | AU759103B2 (es) |
| BR (1) | BR9902019A (es) |
| CA (1) | CA2264260A1 (es) |
| NZ (1) | NZ334839A (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0953641A3 (en) * | 1998-03-26 | 2002-03-13 | Pfizer Products Inc. | Polynucleotide molecules encoding neospora proteins |
| ES2263317B2 (es) * | 2003-12-04 | 2007-10-01 | Universidad Complutense De Madrid | Uso del gen ncsag4 para el diagnostico y prevencion de la neosporosis, y como marcador para el analisis de la patogenia. |
| KR20090051129A (ko) * | 2004-04-05 | 2009-05-20 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
| ES2319242B1 (es) | 2005-12-23 | 2009-12-01 | Laboratorios Hipra, S.A. | Aislado avirulento de neospora canimum y sus usos. |
| ES2326770B1 (es) | 2007-07-13 | 2010-07-26 | Universidad Complutense De Madrid | Uso de un nuevo aislado de neospora caninum para el desarrollo de pruebas de diagnostico y para la fabricacion de productos para el tratamiento y prevencion de la infenccion causada por neospora. |
| DK2310046T3 (da) * | 2008-06-27 | 2016-04-25 | Zoetis Services Llc | Hidtil ukendte adjuvanssammensætninger |
| CN101831495B (zh) * | 2010-04-30 | 2013-06-19 | 新疆出入境检验检疫局检验检疫技术中心 | 一种牛新孢子虫病的检测方法及应用 |
| CA2868391A1 (en) * | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same |
| FR2994193B1 (fr) | 2012-08-02 | 2016-05-20 | Vitamfero | Souches mutantes de neospora et leurs utilisations |
| CN102838984B (zh) * | 2012-09-12 | 2014-06-04 | 浙江理工大学 | 一种胰凝乳蛋白酶保护金纳米团簇荧光材料的制备方法 |
| CN107325166A (zh) * | 2017-05-15 | 2017-11-07 | 华中农业大学 | 柔嫩艾美耳球虫表面抗原基因sag6所编码的重组蛋白及其应用 |
| CN110407944B (zh) * | 2018-04-29 | 2023-04-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 隐孢子虫多表位基因片段cpmcef及其融合蛋白和应用 |
| CN110183527B (zh) * | 2019-05-21 | 2021-03-12 | 中国农业大学 | 一种新孢子虫NcMIC26抗原及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3940598A1 (de) * | 1989-12-08 | 1991-06-13 | Behringwerke Ag | Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung |
| FR2625099B1 (fr) * | 1987-12-24 | 1991-06-14 | Transgene Sa | Proteines et leur procede de preparation, sequences d'adn, anticorps et leur application, poxvirus, cellules transformees ou infectees et compositions pharmaceutiques utiles dans la prevention de la toxoplasmose |
| US5665542A (en) * | 1989-11-03 | 1997-09-09 | Research Institute Of Palo Alto Medical Foundation | Toxoplasma gondii P28 gene and methods for its use |
| FR2692282B1 (fr) * | 1992-06-15 | 1995-07-13 | Pasteur Institut | Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications. |
| US5643718A (en) | 1993-11-04 | 1997-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Transfection and genetic manipulations in obligate intracellular parasites |
| US5976553A (en) | 1993-11-04 | 1999-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Transfection and genetic manipulations in obligate intracellular parasites |
| FR2714074B1 (fr) * | 1993-12-20 | 1996-03-01 | Pasteur Institut | Promoteurs des gènes GRA1, GRA2, GRA5 et GRA6 de toxoplasma gondii et vecteurs d'expression comprenant lesdits promoteurs. |
| US5889166A (en) | 1996-05-10 | 1999-03-30 | The Regents Of The University Of California | Recombinant neospora antigens and their uses |
| US5707617A (en) | 1994-03-21 | 1998-01-13 | The Regents Of The University Of California | Bovine neospora isolates |
| AU7677896A (en) | 1995-11-09 | 1997-05-29 | Trustees Of Dartmouth College | A vaccine against toxoplasma gondii |
| US6476192B1 (en) * | 1996-04-15 | 2002-11-05 | Nicola C. Lally | Recombinant antigens useful for the serodiagnosis of neosporosis |
| AUPO188396A0 (en) | 1996-08-26 | 1996-09-19 | Insearch Limited | Detection of protozoan parasites |
| ATE271122T1 (de) * | 1996-11-12 | 2004-07-15 | Pfizer | Attenuierter lebender neospora impfstoff |
| AUPO690397A0 (en) | 1997-05-20 | 1997-06-12 | Insearch Limited | Large subunit ribosomal dna of neospora species |
| BR9803232A (pt) * | 1997-08-26 | 2000-01-11 | Pfizer Prod Inc | Vaicna de neospora. |
| ATE352315T1 (de) | 1997-10-20 | 2007-02-15 | Bayer Corp | Neospora impstoff |
| US6071737A (en) | 1998-03-16 | 2000-06-06 | The Regents Of The University Of California | Equine Neospora isolate and its uses |
| EP0953641A3 (en) * | 1998-03-26 | 2002-03-13 | Pfizer Products Inc. | Polynucleotide molecules encoding neospora proteins |
| AUPP371798A0 (en) | 1998-05-26 | 1998-06-18 | Insearch Limited | Parasite antigens |
| US20040131633A1 (en) * | 1999-04-21 | 2004-07-08 | University Of Technology, Sydney | Parasite antigens |
-
1999
- 1999-03-09 EP EP99301746A patent/EP0953641A3/en not_active Withdrawn
- 1999-03-24 AR ARP990101308A patent/AR015252A1/es unknown
- 1999-03-24 CA CA002264260A patent/CA2264260A1/en not_active Abandoned
- 1999-03-25 JP JP11081833A patent/JPH11332583A/ja active Pending
- 1999-03-25 NZ NZ334839A patent/NZ334839A/xx unknown
- 1999-03-25 US US09/276,438 patent/US6600027B1/en not_active Expired - Fee Related
- 1999-03-26 BR BR9902019-0A patent/BR9902019A/pt not_active IP Right Cessation
- 1999-03-26 AU AU22437/99A patent/AU759103B2/en not_active Ceased
- 1999-03-26 CN CN99104381A patent/CN1232087A/zh active Pending
-
2003
- 2003-04-21 US US10/419,341 patent/US20030180785A1/en not_active Abandoned
-
2005
- 2005-04-05 JP JP2005109198A patent/JP2005211082A/ja active Pending
- 2005-04-05 JP JP2005109203A patent/JP2005253467A/ja active Pending
- 2005-04-05 JP JP2005109167A patent/JP2005245456A/ja active Pending
- 2005-04-05 JP JP2005109190A patent/JP2005211081A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11332583A (ja) | 1999-12-07 |
| CN1232087A (zh) | 1999-10-20 |
| EP0953641A2 (en) | 1999-11-03 |
| EP0953641A3 (en) | 2002-03-13 |
| JP2005211081A (ja) | 2005-08-11 |
| BR9902019A (pt) | 2000-05-02 |
| JP2005245456A (ja) | 2005-09-15 |
| JP2005253467A (ja) | 2005-09-22 |
| US6600027B1 (en) | 2003-07-29 |
| CA2264260A1 (en) | 1999-09-26 |
| NZ334839A (en) | 2000-08-25 |
| US20030180785A1 (en) | 2003-09-25 |
| AU759103B2 (en) | 2003-04-03 |
| AU2243799A (en) | 1999-10-07 |
| JP2005211082A (ja) | 2005-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015252A1 (es) | Moleculas de polinucleotido aisladas, moleculas de oligonucleotido, vector recombinante, celula hospedadora transformada, polipeptido aislado osustancialmente purificado, anticuerpo aislado, construccion genetica, celula de neospora modificada, procedimiento para prepararla, vacuna contra laneosporo | |
| ES2545886T3 (es) | Inmunoterapia dirigida a patógenos intracelulares | |
| AU2007201553B2 (en) | Expression system | |
| ES2662801T3 (es) | Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas | |
| AR047345A1 (es) | Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes | |
| CN103981204B (zh) | 一种有活性的金鱼Tgf2转座子重组转座酶蛋白的表达方法 | |
| CN108912221A (zh) | 用于生产重组融合蛋白的辅助蛋白、编码基因、重组融合蛋白、重组表达载体及制备方法 | |
| WO2003106684A3 (en) | PROCESS FOR THE SIMULTANEOUS PRODUCTION OF SEVERAL PROTEINS; VECTORS AND CELLS USED IN THIS PROCESS | |
| ES2398492T3 (es) | Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1 | |
| TW200716166A (en) | Lawsonia intracellularis immunological proteins | |
| Kalyanasundaram et al. | Comparative immunoprophylactic efficacy of Haemonchus contortus recombinant enolase (rHcENO) and Con A purified native glycoproteins in sheep | |
| NZ598605A (en) | Vaccine against african horse sickness virus | |
| ES2244993T3 (es) | Metodo recombinante para la preparacion de un antigeno completo de malaria gp190/msp1. | |
| Makoff et al. | Protective surface antigen P69 of Bordetella pertussis: its characterization and very high level expression in Escherichia coli | |
| WO2006102901A3 (en) | Immunogenic egfr peptides comprising foreign t cell stimulating epitope | |
| EP1412374A4 (en) | NEW PGC-1 ISOFORMS AND THEIR USES | |
| US20140322257A1 (en) | Fusion proteins representing different ns: proposal for a vaccine against allergy to mites | |
| TW200801034A (en) | Novel sea lice vaccine | |
| ZA200602107B (en) | Piroplasmid vaccine | |
| EP1233024A3 (en) | 25466, a human transporter family member and uses therefor | |
| AR041243A1 (es) | Vacuna para ostertagia | |
| AR017709A1 (es) | Molecula de polinucleotido aislada, vector recombinante, celula hospedadora recombinante, proteina sustancialmente purificada, polipeptidosustancialmente purificado, fragmento peptidico, anticuerpo, constructo genetico, celula de neospora transformada, procedimiento para modificar celulas deneospora | |
| PE20241070A1 (es) | Inmunocitoquina para activar el receptor il-10ra humano y su uso | |
| WO2004056316A8 (en) | Vaccines against hiv-1 tat protein to generate neutralizing antibodies | |
| AR040830A1 (es) | Vacuna para combatir la infeccion que produce la mastitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |